Tanya S.
- Country
- France
- Department
- Neuromyologie, Hôpital Pitié-Salpetriere
Research Overview
- A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of EDG-5506 on Safety, Biomarkers, Pharmacokinetics, and Functional Measures in Adults and Adolescents with Becker Muscular Dystrophy
- Long-term Safety and Biomarker Assessment of EDG-5506 in Adults and Adolescents with Becker Muscular Dystrophy: An Open-Label Extension Study
- Phase 1-2 Multicenter Study on Safety and Efficacy of Intravenous GNT0006 in FKRP-Related Limb-Girdle Muscular Dystrophy (LGMDR9) Patients
Data & Insights
Has run more than one trial at 17 of 28 partner sites.
Specializations
Muscular Dystrophy Research
This investigator demonstrates extensive involvement in treating various forms of muscular dystrophy, with particular focus on Becker Muscular Dystrophy (BMD) and limb-girdle muscular dystrophy. Their research encompasses innovative therapeutic approaches for these progressive muscle disorders.
- FKRP-related muscular disorders
- Gene therapy applications
- Novel therapeutic compounds
Neuromuscular Disorders
The investigator specializes in treating complex neuromuscular conditions, including Myotonic Dystrophy Type 1 (DM1). Their work explores therapeutic interventions aimed at improving muscle function and patient mobility.
- Muscle function assessment
- Progressive muscle weakness management
- Therapeutic intervention strategies
Treatment Development
This clinical researcher focuses on evaluating novel therapeutic approaches, including gene therapy and pharmaceutical interventions. Their work encompasses both adult and adolescent patient populations, with emphasis on safety and efficacy assessment.
- Safety and tolerability studies
- Biomarker evaluation
- Treatment optimization protocols
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.